Can strug­gling Iterum turn the cor­ner to an an­tibi­ot­ic suc­cess sto­ry? They will know in six months

5 years ago
FDA+

Buried in Im­muno­core's IPO fil­ings? A kick­back scheme from a now for­mer em­ploy­ee

5 years ago
Startups

Covid-19 roundup: Mod­er­na dou­bles down on Covid-19 with new boost­er tri­als; Aus­tralia plans do­mes­tic pro­duc­tion of ...

5 years ago
Coronavirus

Lon­za look­ing to build on 'd­if­fer­en­ti­at­ed ad­van­tage' in Covid-19, CD­MO mar­ket­place in 2021

5 years ago
Pharma
Manufacturing

News brief­ing: Jef­frey Lei­den to chair Tmu­ni­ty board of di­rec­tors; Op­di­vo wins new ap­proval in ad­vanced RCC

5 years ago
News Briefing

Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

5 years ago
People

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the ...

5 years ago
Bioregnum
Opinion

As­traZeneca's Calquence nabs an­oth­er win against Im­bru­vi­ca, but Eli Lil­ly is on its heels

5 years ago
R&D

Al­bireo just ad­vanced down to the 10-yard line at the FDA. And Ron Coop­er’s team is get­ting prepped for the next ...

5 years ago
FDA+

Roche amps up its bis­pe­cif­ic at­tack on Eylea with more PhI­II da­ta — but just how threat­en­ing is it?

5 years ago
R&D

Har­vard spin­out kicks off 2021 with a crossover round and sights set on the clin­ic

5 years ago
Financing

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the ...

5 years ago
Coronavirus

Fast on Glax­o­SmithK­line's heels, Au­rinia wins OK to steer a sec­ond lu­pus nephri­tis drug straight to the mar­ket

5 years ago
R&D

Yale can­cer spe­cial­ist Char­lie Fuchs tapped as new glob­al de­vel­op­ment chief for Roche/Genen­tech

5 years ago
People

Neu­vo­gen un­cloaks with broad plan of at­tack for whole-cell can­cer vac­cines, clin­i­cal hopes with­in the year

5 years ago
Startups

News brief­ing: Eli Lil­ly com­pletes $1B+ Pre­vail buy­out; El­zon­ris ap­proved in Eu­rope for adults

5 years ago
News Briefing

Flush with cash to change the gener­ics sup­ply chain, Civi­ca Rx looks to break ground on first in-house man­u­fac­tur­ing ...

5 years ago
Manufacturing

Can a new CRISPR tech­nique un­lock the se­crets of how can­cer spreads?

5 years ago
Discovery
In Focus

Diem Nguyen tapped to lead 'point of in­flec­tion' at Xalud Ther­a­peu­tics; Di­ana Es­co­lar dances her way to Avro­bio CMO

5 years ago
Peer Review

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the ...

5 years ago
R&D

Biden in­sti­tutes reg­u­la­to­ry freeze on first day of pres­i­den­cy

5 years ago
FDA+

In­cyte's PD-1 pri­or­i­ty re­view draws mut­ed cheer — but an­a­lysts say it's all about get­ting a foot in the door

5 years ago
FDA+

Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

5 years ago
R&D

Covid-19 roundup: Eu­rope to seek clar­i­fi­ca­tion on Pfiz­er/BioN­Tech de­lays; J&J pre­dicts 100M dos­es for US by April

5 years ago
Coronavirus
First page Previous page 752753754755756757758 Next page Last page
A service from the Financial Times